Neurothera Labs Inc.
NTLX.V
TSX
| 09/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -9.23% | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -9.23% | ||||
| Cost of Revenue | -23.08% | ||||
| Gross Profit | -1.78% | ||||
| SG&A Expenses | -23.08% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -23.08% | ||||
| Operating Income | 44.38% | ||||
| Income Before Tax | 44.38% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 44.38% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 44.38% | ||||
| EBIT | 44.38% | ||||
| EBITDA | 40.49% | ||||
| EPS Basic | -- | ||||
| Normalized Basic EPS | -- | ||||
| EPS Diluted | -- | ||||
| Normalized Diluted EPS | -- | ||||
| Average Basic Shares Outstanding | -- | ||||
| Average Diluted Shares Outstanding | -- | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||